AdhIL2

AdhIL2 is a replication-deficient adenoviral gene therapy vector designed to deliver and express the human interleukin-2 (hIL2) gene. Developed by researchers at the Baylor College of Medicine's Center for Cell and Gene Therapy, it is primarily utilized as a component of an autologous tumor vaccine strategy for B-cell malignancies such as non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). The vector transduces malignant cells to secrete IL-2, a potent cytokine that stimulates the proliferation and activation of T cells. In clinical applications, AdhIL2 is often administered in combination with another adenoviral vector expressing CD40 ligand (AdhCD40L) to enhance the co-stimulatory potential of tumor cells, thereby overcoming immune evasion and inducing a specific MHC-restricted cytotoxic T-lymphocyte response against the patient's cancer.

Other names

Adenoviral human Interleukin-2Ad-IL2Ad-IL-2Ad-IL 2